soluble receptor activator of nuclear factor κb ligandosteoprotegerin ratio is increased in systemic lupus erythematosus patients可溶性受体激活核因子κb ligandosteoprotegerin系统性红斑狼疮患者的比例增加.pdf
文本预览下载声明
Carmona-Fernandes et al. Arthritis Research Therapy 2011, 13:R175
/content/13/5/R175
RESEARCH ARTICLE Open Access
Soluble receptor activator of nuclear factor B
ligand/osteoprotegerin ratio is increased in
systemic lupus erythematosus patients
1† 1,2† 1 1,3
Diana Carmona-Fernandes , Maria José Santos , Inês Pedro Perpétuo , João Eurico Fonseca and
Helena Canhão1,3*
Abstract
Introduction: Systemic lupus erythematosus (SLE) patients have lower bone mineral density and increased fracture
risk when compared with healthy individuals, due to distinct factors and mechanisms. Bone remodeling is a tightly
orchestrated process dependent on several factors, including the balance between receptor activator of nuclear
factor B ligand (RANKL) and osteoprotegerin (OPG).
Our aim was to assess serum OPG and soluble RANKL (sRANKL) levels as well as sRANKL/OPG ratio in female SLE
patients and compare it with female controls.
Methods: We have evaluated 103 SLE patients and 114 healthy controls, all Caucasian females. All participants
underwent a clinical and laboratory evaluation. sRANKL and OPG were quantified in serum by ELISA based
methods. sRANKL, OPG and sRANKL/OPG ratio levels were compared between SLE patients and age, sex and race
matched healthy controls. For SLE patients, a multivariate analysis was performed, to find the possible predictors of
the changes in sRANKL, OPG and sRANKL/OPG ratio levels.
Results: Although sRANKL levels did not differ between the two groups, serum OPG was lower in SLE patients (P
0.001). This led to an increased sRANKL/OPG ratio (P = 0.010) in the patients’ group.
The multivariate analysis was performed considering age and other clinical and laboratorial
显示全部